Clinical trial

Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)

NCT03542461

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2017-09-25

PhasePHASE3

Study timeline

Study start (actual)2017-09-25Date precision: day

Registry last updated2022-10-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Squamous Non-small Cell Lung Cancerunresolved

Interventions

Nivolumab 10 MG/ML Intravenous SolutionDRUG

Best Supportive CareOTHER

Sponsors & collaborators

Gruppo Oncologico Italiano di Ricerca Clinicalead sponsor

Mipharm S.p.A.collaborator

Bioikos Ambiente Srlcollaborator

Istituto Toscano Tumoricollaborator

Temas srlcollaborator

Bristol Myers Squibb Srl Italiacollaborator

Mapped research locations

RomaItaly2 NaplesItaly1 GenovaItaly1 PadovaItaly1 BolognaItaly1 FlorenceItaly1 PisaItaly1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03542461 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.